# Research article

**Open Access** 

# Branched-chain amino acid aminotransferase and methionine formation in Mycobacterium tuberculosis

Erik S Venos, Marvin H Knodel, Cynthia L Radford and Bradley J Berger\*

Address: Chemical & Biological Defence Section, Defence R&D Canada – Suffield, Box 4000 Station Main, Medicine Hat, Alberta, T1A 8K6, Canada

Received: 09 June 2004 Accepted: 07 October 2004

Email: Erik S Venos - esvenos@interchange.ubc.ca; Marvin H Knodel - Marvin.Knodel@drdc-rddc.gc.ca; Cynthia L Radford - Cynthia.Radford@drdc-rddc.gc.ca; Bradley J Berger\* - Brad.Berger@drdc-rddc.gc.ca \* Corresponding author

Published: 07 October 2004

BMC Microbiology 2004, 4:39 doi:10.1186/1471-2180-4-39

This article is available from: http://www.biomedcentral.com/1471-2180/4/39

© 2004 Venos et al; licensee BioMed Central Ltd.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (<u>http://creativecommons.org/licenses/by/2.0</u>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### Abstract

**Background:** Tuberculosis remains a major world-wide health threat which demands the discovery and characterisation of new drug targets in order to develop future antimycobacterials. The regeneration of methionine consumed during polyamine biosynthesis is an important pathway present in many microorganisms. The final step of this pathway, the conversion of ketomethiobutyrate to methionine, can be performed by aspartate, tyrosine, or branched-chain amino acid aminotransferases depending on the particular species examined.

**Results:** The gene encoding for branched-chain amino acid aminotransferase in *Mycobacterium tuberculosis* H37Rv has been cloned, expressed, and characterised. The enzyme was found to be a member of the aminotransferase IIIa subfamily, and closely related to the corresponding aminotransferase in *Bacillus subtilis*, but not to that found in *B. anthracis* or *B. cereus*. The amino donor preference for the formation of methionine from ketomethiobutyrate was for isoleucine, leucine, valine, glutamate, and phenylalanine. The enzyme catalysed branched-chain amino acid and ketomethiobutyrate transamination with a Km of 1.77 - 7.44 mM and a Vmax of 2.17 - 5.70 µmol/min/mg protein, and transamination of ketoglutarate with a Km of 5.79 - 6.95 mM and a Vmax of 11.82 - 14.35 µmol/min/mg protein. Aminooxy compounds were examined as potential enzyme inhibitors, with O-benzylhydroxylamine, O-t-butylhydroxylamine, carboxymethoxylamine, and O-allylhydroxylamine yielding mixed-type inhibition with Ki values of 8.20 - 21.61 µM. These same compounds were examined as antimycobacterial agents against *M. tuberculosis* and a lower biohazard *M. marinum* model system, and were found to completely prevent cell growth. O-Allylhydroxylamine was the most effective growth inhibitor with an MIC of 78 µM against *M. tuberculosis*.

**Conclusion:** Methionine formation from ketomethiobutyrate is catalysed by a branched-chain amino acid aminotransferase in *M. tuberculosis*. This enzyme can be inhibited by selected aminooxy compounds, which also have effectiveness in preventing cell growth in culture. These compounds represent a starting point for the synthesis of branched-chain aminotransferase inhibitors with higher activity and lower toxicity.

# Background

Tuberculosis remains one of the leading causes of worldwide mortality and morbidity, infecting an estimated 8 million people annually with approximately 2 million deaths [1]. The situation regarding the control of tuberculosis has significantly worsened over the last decades, with the spread of multidrug resistant strains. In the absence of an effective vaccine for tuberculosis, there is an urgent need for the development of novel antimycobacterial agents. The study of mycobacterial biochemistry assists this development through the identification and characterization of cellular enzymes amenable to therapeutic inhibition.

Polyamine synthesis and its associated methionine (Met) regeneration pathway (Figure 1) are known to be potential drug targets in a variety of microorganisms [2-4]. The synthesis of polyamines is essential during periods of DNA replication, although the exact physiological role of these compounds remains unclear [3]. The production of spermidine from putrescine, or spermine from spermidine, consumes the amino acid Met in a 1:1 stoichiometry yielding methylthioadenosine (MTA) as a byproduct. As Met biosynthesis is energetically expensive, and many organisms lack the ability to synthesize the amino acid, a unique pathway exists which recycles Met from MTA. To date, the entire pathway has only been fully characterised in the Gram-negative bacterium Klebsiella pneumoniae [5-11] and the Gram-positive bacterium Bacillus subtilis [12-14] Selected individual enzymes active in the pathway have been studied in a wide variety of eukaryotic and prokaryotic organisms [7,15-20]. For Mycobacterium spp., only methionine adenosyltransferase has been cloned, expressed, and fully characterised [21].

The final step in Met regeneration is the transamination of ketomethiobutyrate (KMTB) by an aminotransferase. The specific aminotransferase responsible for the reaction has been identified and characterised in a number of microorganisms, including malaria, African trypanosomes, K. pneumoniae, B. subtilis, and B. anthracis [7,16,17]. In the lower eukaryotes Plasmodium falciparum, Trypanosoma brucei brucei, Giardia intestinalis, and Crithidia fasciculata, this reaction is catalysed by the subfamily Ia enzyme aspartate aminotransferase [17]. In K. pneumoniae, however, the reaction was performed by the close homologue tyrosine aminotransferase, which is also a member of subfamily Ia [7]. Gram-positive bacteria and archaea appear to lack any subfamily Ia homologues in their genomes, and B. subtilis, B. cereus, and B. anthracis were recently found to catalyse Met regeneration via a branched-chain amino acid aminotransferase (BCAT) [16]. This enzyme is a member of family III, along with D-amino acid aminotransferase (DAAT), and is unrelated structurally to family I enzymes [22]. Intriguingly, B. subtilis and B. cereus/B. anthracis utilised BCAT enzymes from separate subfamilies (IIIa vs. IIIb respectively). As *Mycobacterium spp.* also appear to have no subfamily Ia aminotransferase sequences ([16], and data not shown), it would be expected that *M. tuber-culosis* also catalyses the conversion of KMTB to Met via a BCAT. In this paper, we report the identification, cloning, and functional expression of a single BCAT from *M. tuber-culosis*. In addition, this enzyme has been demonstrated to actively catalyse Met formation and is subject to inhibition by a variety of aminooxy compounds.

## Results

# Branched-chain amino acid aminotransferase in M. tuberculosis

The complete, published genome of *M. tuberculosis* H37Rv was found to contain a single gene with a very high sequence homology to either *B. subtilis* YbgE or YwaA, which are both known to be subfamily IIIa BCATs [16,23]. In contrast, the tuberculosis genome did not contain a homologue to *B. subtilis* YheM, *B. cereus* BCAT, or *B. anthracis* BCAT, which are all subfamily IIIb aminotransferases [16]. This relationship can be clearly seen in Figure 2A, where selected family III aminotransferases have been aligned and an unrooted tree constructed. The putative *M. tuberculosis* BCAT gene, Rv2210c, has not been previously cloned, expressed, or characterised. It is interesting to note that the *M. tuberculosis* genome contains a single BCAT homologue and no obvious DAAT homologue.

Examination of complete and incomplete genome projects for Mycobacterium spp. uncovered a single gene in M. leprae, M. bovis, M. marinum, M. ulcerans, M. avium, and M. smegmatis with an extremely high identity to Rv2110c. Together, with other subfamily IIIa aminotransferases, the putative mycobacterial sequences were aligned and a cladogram constructed (Figure 2B). The M. tuberculosis and M. bovis sequences were identical, as were the M. marinum and M. ulcerans sequences. Aside from M. bovis, all the mycobacterial BCAT sequences were found to be 85 -88% identical to the M. tuberculosis sequence. However, the tuberculosis sequence was 57% identical to the putative BCAT from Streptomyces coelicolor and 45% identical to B. subtilis YbgE. Figure 2B highlights the fact that the mycobacterial BCAT sequences are more closely related to eukaryotic enzymes than to most other bacterial homologues. There was little sequence conservation with enzymes found in subfamily IIIb, with only 27% identity to the E. coli BCAT, 18% to the B. anthracis BCAT, and 15% to B. subtilis YheM.

The low level of sequence conservation outside of the genus can be seen in the alignment of selected BCAT sequences shown in Figure 3. Only 19 residues are completely conserved across even this small sequence sampling. Interestingly, of the residues found by X-ray



#### **Figure I**

**The formation of Met from KMTB.** The pathway of polyamine synthesis and subsequent Met regeneration from MTA, as known from *K. pneumoniae* [11] and *B. subtilis* [12], is shown. Solid arrows represent steps that have been characterised in *M. tuberculosis* (present study and [21]). The conversion of KMTB to Met is shown at the top in bold. KIC = ketoisocaproate, KIV = ketoisovalerate, and KMV = ketomethylvalerate.



**Relationship of M. tuberculosis BCAT to other family III aminotransferases.** In (A) selected subfamily IIIa and IIIb aminotransferases were aligned and a tree constructed by the neighbor-joining method [49] in order to define the subfamily membership of the *M. tuberculosis* BCAT (in blue). In (B) subfamily IIIa BCATs were aligned and a cladogram constructed by the neighbor-joining method. The numbers represent the bootstrap values (in percentage) for each branch point.

crystallography to be important in substrate binding to the *E. coli* BCAT [24], only K228(K159) and T339(T257) were conserved across the 13 sequences in Figure 3. The residues in parentheses represent the corresponding position in the *E. coli* BCAT. Of these two residues, K228(K159) is the PLP binding site and would be expected to be invariant. If one excludes the only DAAT in Figure 3, then Y91(Y31), F96(36), Y233(164), and A340(A258) can be added to this conserved list of residues important for substrate binding in the *E. coli* BCAT. Clearly, sequence conservation is very low across family III.

# Expression and characterization of the branched-chain amino acid aminotransferase

The putative *M. tuberculosis* BCAT was cloned as a decahistidine fusion protein for expression in *E. coli*. To prevent complete inclusion of the recombinant protein, it was necessary to induce expression with a relatively low concentration of IPTG (0.1 mM) at 20°C for 20 hr. Under these conditions, sufficient soluble material was produced and purified over Ni<sup>2+</sup> affinity columns (Figure 4). Assay of the eluted material with 2 mM each of ADEFGHIKL-NQRSTVWY and 1 mM KMTB resulted in appreciable Met production (data not shown), demonstrating that the enzyme was active and catalysed Met formation.

The purified enzyme was screened against 2 mM of each individual amino acid and 1 mM KMTB to determine the amino donor range for Met regeneration. Isoleucine, leucine, and valine were found to be the most effective substrates (Figure 5), while glutamate and phenylalanine were also active as amino donors. Tyrosine and tryptophan were found to have a much lesser ability to transaminate KMTB and all other amino acids were inactive. The five most active amino donors were more closely examined in order to determine their kinetic parameters (Table 1). The Km for Leu, Ile, and Val ranged from 1.77

<ul> <li>M. BOLT</li> <li>M. BOLT</li></ul>		10	20	30	40	50	60	70	80	90	100
NIL TRANS         TV JAN NE ALDOLDS LUNC         Common Net To Let LUE ALDOLDS LUNC         Common Net To Let LUE ALDOLDS LUNC ALDOLDS LU			••••••	····   · · · ·   · · · ·		···	· ·   · · · ·   · · ·			· · · ·   · · · ·	
Bit Bit - This Stabule         - TVBATER ALL DARAWER ALL D	MC-BCAT	MISGSLQF		IVLRAVNPA	IDAQRESML	REPGEGRIHII	JHMVSIDIAE-	GRGWHNARVI	PIGPIELDPS	AIVLHIAQEV	FEGLA
<ul> <li>Serie Construction of the series of the serie</li></ul>	Mm_BCAT	MISGSLOF		IVLRAVNPA	TENEDVCTI	APGF GRIHII	JHMVSIDIAE-		CVCDIELDPS	AIVLHIAQEV	FEGLA
<ul> <li>HUBBAN - HYDSOLEP - TVSIGLAEP TVSIGAEP TDAEPES ILLEE OF GRAFTING SIDD TD - GRAFTER MUTTER TO PERSIDE TAKEN AND AND AND AND AND AND AND AND AND AN</li></ul>	Mu-DCAT	MIRGSQQF		IVIRATIFA	TEAERVOIL	ADP GF GRIHII	DIMUSIDE DE-		CVCDIELDES	AIVINAQEV	FEGLA
HIGS DE LANDORS THE SALE AND	MI_BCAT	MIRGSQQF			TDAERVOIL	ADF GF GKIHII	UNVSIDEDE-		DVCDTOIDDS	ATVINZACEV	FEGLK
Barbor	Ma-BCAT	MTSCSLEE-		TVSLSAILV	TDABRESID	AEI GI GRIIIII	JUMUSTEVDET	FACECWHDARVI	DVCDIFIDDS	ATVINZOET	FEGLIK
SPEAN      MTTTTL:      MESSMESS BALLANEVERAPTION/TINTECROMODQUEYA LISUPATIVUI/YADDESTIFUEX         B=BAN      ME-KLIEK      MESSMESS BALLANEVERAPTION/TINTECROMODQUEYA LISUPATIVUI/YADDESTIFUEX         B=BAN      ME-KLIEK      MESSMESS BALLANEVERAPTION/TINTE	Me-BCAT	MNSGPLEF		TVSANTNPA	TDALKEIII TDAVRESTI.	AND GEGKVYTI	HMUSIDIDEI	DEGWHNAOVI	PYGPIOLDPS	AIVLHYGOFT	FEGLK
<ul> <li>N. H. H. KUER, T. M. KUER, KU</li></ul>	SC-BCAT	MTTRTIFI		IVSANINIA	COCEDAATI	AND CECRUETI	JUMVTIKWTE_		DVADI GIDDA	TMVINVOET	FEGLIK
BEAN         MCCNIGSAECTGEGGSKEWUGTEKARDLIVTEATLIJKEKPDENNLYGTVTTDIMLIVENSS         DEGKEN           ACCNIGSAECTGEGGSKEWUGTEKARDLIVTEATLIJKEKPDENNLYGTVTTDIMLIVENSS         TITKAA         TITKAA           VIN-EQUITENSEV         TITKAA         TITKAA           VIN-EQUITENSEV         TITKAA         TITKAA           VIN-EQUITENSEV         10         120         190         200           MORADS 105FRADAMALIASSABRIATELEP-DAVFESLIQLIAVUKAWPGAGGEEALLUPFTATPEGLUVRPATYR-         LILASSAAVEK           MIN-BCAT         ATRIADSS 105FRADAMALIASSABRIATELEP-DAVFESLIQLIAVUKAWPGAGGEEALLUPFTATPEGLUVRPATYR-         LILASSAAVEK           MIN-BCAT         ATRIADSS 105FRADAMALIASSABRIATELEP-DELEP-LESTESLIQLIAVUKAWPGAGGEEALLUPFTATPEGLUVRPATYR-         LILASSAAVEK           MIN-BCAT         ATRIADSS 105FRADAMAALIASSABRIATELEP-DEVETESLIQLIAVUKAWPGAGGEEALLUPFTATPEGLUVRPATYR-         LILASSAAVEK           MIN-BCAT         ATRIADSS 105FRADAMAALIASSABRIATELEP-DEVETESLIQLIAVUKAWPGAGGEEALLUPFTATEPGLUVRPATYR-         LILASSAAVEK           MIN-BCAT         ATRIADSS 105FRADAMAALIASSABRIATELEP-DEVETESLIQLIAVUKAWPAGGEESLILLEPTATEPGLUVRPATYRAVEK-         LILASSAAVEK           MIN-BCAT         ATRIADSS 105FRADAMAALIASSABRIATELEP-DEVETESLIGULIAVUKAWPAGGEESLILLEPTATEFGLUVRPATYRAVEK-         LILASSAAVEK           MIN-BCAT         ATRIADSSAAVERANGENDAELSAAVEK         LILASSAAVEK           MIN-BCAT         ATRIADASI 1055000000000000000000000000000000000	Be-BCAT	MN-KLIER		EKTUAAKEK	PDP	SSLGEGOVETI	VMEVMDVEE-	GIGWHHPRIA	PYAPI.TI.DPS	SSVEHYGOAV	FEGLK
BECAN HELEONALD FOR THE ADDRESS OF THE ADDRESS O	US-BCAT	MDCSNCSAFCTO	FCCSKEW	TERARDI TUTDA	ם המששע דע ב דדו גבעסאס	NNI VECTVETI	DIME VHDIEE	FECWERPHIK	DI ONI SI UDO	SSVENIQUAV	FEGLIK
BE EXIT	Fo-BCAT						TTKKAD-	YIWENGEMU	BMEDVKANN L HÖMPRHUK	ISHAL HYGTSV	FEGIR
Be-DART	Ba-BCAT						VN-	-FOWIELNGEEV	PKDFAKUSUY	DHGYLYGDGV	FEGIR
110         120         130         140         150         160         170         180         180           MC-BCX         ATRANGESTUSFRADAMARLESSARELATELE-DAVE IESLEQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSFRADAMARLESSARELATELE-DAVE IESLEQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSFRADAMARLESSAREMATEELE-EELF IESLIQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSFRADAMARLESSAREMATEELE-EELF IESLIQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSFRADAMARLESSAREMATEELE-EELF IESLIQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSFRADAMARLESSAREMATEELE-EELF IESLIQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSFRADAMARLESSAREMATEELE-EEVT IESLEQILAUKAWENGGEBALIVER FITATEGIGVPRATUN-VLILASPAATEK           MC-BCX         ATRANGESTUSTRADAMARLESSARTMEPEL-EEVT IESLEQILAUKAWENGGEBALIVERENTITETTEGIGVPRATULASPAATEK	BS-DAAT							MKVLVNGRLT	GRSEASIDLE	DRGYOFGDGT	YEVIR
110         120         130         140         150         140         170         180         190         200           NN-BGX         A:RWADGS1VSFRADANARLBSARKLAIFELP-DAVFIESLAQLIAVDKAWFGAGGEBALVILRFTFATEGLGVRFATYRYLLIASPACHFK           NN-BGX         A:RWADGS1VSFRADANARLBSARKLAIFELP-DAVFIESLAQLIAVDKAWFGAGGEBALVILRFTFATEGLGVRFATYRYLLIASPACHFK           NN-BGX         A:RWADGS1VSFRADANARLBSARKLAIFELP-DAVFIESLAQLIAVDKAWFGAGGEBALVILRFTTATEGLGVRFATYRYLLIASPACHFK           NN-BGX         A:RWADGS1VSFRADANARLBSARKLAIFELP-DAVFIESLAQLIAVDKAWFGAGGEBALVILRFTTATEGLGVRFATYRYLLIASPACHFK           NN-BGX         A:RWADGS1VSFRADANARLBSARKLIFELP-DEVFIESLEQLIAVDNWAPAGGEBALVILRFTTATEGLGVRFASKYRYLLIASPACHFK           NN-BGX         A:RWADGS1VSFRADANARLBSARKLIFELP-DEVFIESLEQLIAVDNWAPAGGEBALVILRFTVIATEGLGVRFASKYRYLLIASPACHFK           NB-BGX         A:RRFDGVNFRLPENGALPDSAKTUREPLP-EVITTEGLGVRADKKKSISUTERFMILTEVGLGVRFASKYRYLLIASPACHFK           SEBCX         YS         A:RRFDGVNFRLPENGALPDSAKTUREPTFYSDIDLEHEACHUTWERKS-SISUTERFMILTEVGLGVRAPKKYLLIASPACHFK           SEBCX         YS	20 21212							11111211101121	01001101010	bridi gi oboi	
110         120         130         140         150         160         170         180         190         280           MC-BOX         APPARAGETUSPEADANAALUSSARRALTPEL-DAYF LESLAGULAVDKAWVCAGGEEALVLAPF IATEPEGLAWPATQTA											
NH-BOXT       AVENADGSTVSFRADANAALLRSSARRLATPELE-DAVFTESLAQLIAVDKAWVPGAGGEBALYLRPFTFATEPELGVRPATQYRYLLIASPAGNYFK         MB-BOXT       AVENADGSTVSFRADANAALLSSSARRLATPELE-DAVFTESLAQLIAVDKAWVPGAGGEBALYLRPFTFATEPELGVRPATQYRYLLIASPAGNYFK         MB-BOXT       AVENADGSTVSFRADANAALLSSSARRATPELE-DEFTESLIQLIAVDKAWVPGAGGEBALYLRPFTTATEPELGVRPATQYRYLLIASPAGNYFK         MI-BOXT       AVENADGSTVSFRADANAALLSSSARRATPELE-DEFTESLIQLIAVDNAWVPAGGEBALYLRPFTTATEPEGGVRPATQYRYLLIASPAGNYFK         MI-BOXT       AVENADGSTVSFRADANAALSSSARRLATPELE-DEFTESLIQLIAVDNAWVPAGGEBALYLRPFTTATEPEGGVRPATQYRYLLIASPAGNYFK         MI-BOXT       AVENADGSTVSFRADANAALSSSARRLATELPEL-DEFTESLQUIAVDNAWVPAGGEBALYLRPFTTATEPEGGVRPRAYQRYLLIASPAGNYFK         MI-BOXT       AVENADGSTVSFRADANAALSSSARRLATPELE-DEFTESLQUIAVDNAWVPAGGEBALYLRPFTTATEPEGGVRPRAYQRYLLIASPAGNYFK         MI-BOXT       AVENDOSTVSFRADANAALGSSARRLATPELP-DEFTESLQUIAVDNAWVPAGGEBELYLRPFTTATEPEGGVRPRAYQRYLLIASPAGNYFK         MI-BOXT       AVENDOSTVSFRADANAALGSSARRLATPED-DETTESLQUIAVDNAWVPAGGEBELYLRPFTTATEPEGGVRPRAYQRYLLIASPAGNYFK         MI-BOXT       AVENDOSTVSFRADANAALGSSARRLATPED-SENELECIQUIVLDQUWPRAVGESTURPATURPFTTATEPEGGVRPRAYQRYLLIASPAGNYFK         MI-BOXT       TOTSIKG-FWVFTREBENGARBENGSGVRTHPFTVATTESLQUITASPAGNYK         MI-BOXT       TOTSIKG-FWVFTREBENGARBENGGVRTHPFTVESGGSARLTPELSCELEGTEDEL         MI-BOXT       GOTTSIKG-FWVFTREBENGARBENGGVRTHPFTVESGGSARLTPELSCELEGTEDEL         MI-BOXT       GOTTSIKG-FWVFTREBENGARBENGGGVRTHPFTVESGGSARLTPELSCELEGTEDEL		110	120	130	140	150	160	170	180	190	200
M-BCN M-BCN APRNADGSIVSFRADANAARLESSARRAIPELP-BEYTESLQUIAVDKAWVPGAGGEEALYLRPFIATEPGLOVRPATOYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAARLESSARRAIPELP-BEYTESLQUIAVDKAWVPGAGGEEALYLRPFIATEPGLOVRPACYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAARLESSARRAIPELP-BEYTESLQUIAVDKAWVPFAGGEEALYLRPFIATEPGLOVRPACYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAARLESSARRAIPELP-BEYTESLQUIAVDKAWVPFAGGEEALYLRPFIATEPGLOVRPACYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAARLESSARRAIPELP-BEYTESLQUIAVDKAWVPFAGGEEALYLRPFIATEPGLOVRPACYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAARLESSARRAIPELP-BEYTESLQUIAVDKAWVPFAGGEESLYLRPFIATEPGLOVRPACYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAARLESSARRAIPEL-DEYTESLQUIAVDKAWVPFAGGEESLYLRPFIATEPGLOVRPARYR-YLLIASPACHYR M-BCN APRNADGSIVSFRADANAALRSSARRAIPEL-EXVTESLQUIAVDKAWVPFAGGESLYLRPFIATEPGLOVRPARYRYYLLIASPACHYR B-BCN APRNADGSIVSFRADANAALRSSARRAIPEL-EXVTESLQUIAVDKAWVPAGGESLYLRPFIATEPGLOVRPARYRYYLLIASPACHYR B-BCN APRNADGSIVSFRADANAARLSSARRAIPELP-EXVTESLQUIAVDKAWVPAGGESLYLRPFIATEVGLOVRFANSKYYLLIASPACHYR B-BCN APRNADGSIVSFRADANAARLSSARRAIPEU-EXVTESLQUIAVDKAWVPAGGESLYLRPFIATEVGLOVRFANSKY	Mt-BCAT	AVRWADGSTVS	RADANAARI.				WPGAGGEFAI	VI. RPFIFATER	LOVRPATOVE		CDVFK
ATRADOSTISTERAWANAARLESSARRMAIPELP-EELFIESIJQIIAVDNWWPPAGGEEALYLRPFITATEPGGVRPAQYRYLLIASPAGAYEM MI-SCAT YMWADGSUSTERAWANAARLESSARRMAIPELP-EELFIESIJQIIAVDNWWPPAGGEEALYLRPFITATEPGGVRPAQYRYLLIASPAGAYEM MI-SCAT YMWADGSUSTERAWANAARLESSARRMAIPELP-EELFIESIQIIAVDNWWPPAGGEEALYLRPFITATEPGGVRPAQYRYLLIASPAGAYEM MI-SCAT YMWADGSUSTERAWANAARLESSARRIAIPELP-EELFIESIQIIAVDNWWPPAGGEEALYLRPFUTATEPGGVRPAQYRYLLIASPAGAYEM MI-SCAT YMWADGSUSTERAWANAARLESSARRIAIPELP-EELFIESIQIIAVDNWWPAGGEEALYLRPFUTATEPGGVRPAQYRYLLIASPAGAYEM SCAT YMWADGSUSTERAWANAARLESSARRIAIPELP-EELFIESIQIIAVDNWWPAGGEEALVLRPFUTATEPGGVRPAQYRYLLIASPAGAYEM SCAT YMWADGSUSTERAWANAGAUSTERDAGASRIGMPELP-VDTFIEACOALVAQDEKWPAAGGEEALVLRPFUTATEPGGVRPSNEXTFYLLASPAGAYEM SCAT YMREDGSVATFRPEKNGARPGASSRIGMPELP-VDTFIEACOALVAQDEKWPAAGGEEALVLRPFUTATEPGGVRPSNEXTFYLLASPAGAYEM SCAT YMREDGSVATFRPEKNGARPGASSRIGMPELP-VDTFIEACOALVAQDEKWPAAGGEESLURPFUTATEPGLGVRPSNEXTFYLLASPAGAYEM SCAT YMREDGSVATFRPEKNGARPGASSRIGMPELP-VDTFIEACOALVADDEKWPEYSTASALI IRPAFIGTEBSIGVRPTKTLFVLLASPAGAYEM SCAT CYDSHKG-FVVFFNREHMRENKSKINGETYSUSGSTELMEACODVIKIDQUEKWP-YSTASALI IRPAFIGTEBSIGVRPTNLFVLLASVGYSTGVITAF SCAT CYDSHKG-FVVFFNREHMREHMSKITYRFV9SGSTELMEACODVIKIDQUEKWP-YSTASALI IRPAFIGTEBSIGVRPTNLFVLUSEVGYYES SC-SCAT GG-IAPVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAECCQUVWILDVERKYIELEWGGNIFFVLGSGSGSRLVTFELSGSLIFGITTDGI MI-SCAT GG-IAPVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYIELEWGGNIFFVLGSGSGSRLVTFELSGSLIFGITTDGI SC-SCAT GG-IAPVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYIELEMGGNIFFVLGSGSGSRLVTFELSGSLIFGITTDGI SC-SCAT GG-IAPVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYIELEMGGNIFFVLGSGSGSRLVTFELSGSLIFGITTDGI SC-SCAT GG-IAPVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYVEEMGGNIFFVLGSGSGSRLVTFELSGSLIFGITTDGI SC-SCAT GG-IAPVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYVEEMGGNIFFVLGSGSGSRLVTFELSGSLIFGITTDGI SC-SCAT GFVVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYVEEMGGNIFFVLGSGSSRLVTFELSGSLIFGITTDGI SC-SCAT GFVVSWWSTEVVRACPGGTG-AKFGCNYASLLAQAEAEECCQUVWILDVERKYVEEMGGNIFFVLGSGSSRLVTFELS	Mb_BCAT	AVRWADGSTVS	RADANAARLI	RSSARRIATPEL	P-DAVETES	LROL TAVDKAL	WPGAGGEFAI	VI.RPETEATEPG	LOVREATOYE	VILLASPA	GAVER
ATMONDOSIVERTAINAMARLINGUMMENTICUM LEUFICIDUMENTICUM LANGUELUTERGUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMENTICUMEN	Mm_BCAT	AVEWADCSTUS			D_FFIFIFS	I TOI TAVDIUM	WPRACCEENI	VIDDETIATEDC	I CUPPAKOVE	VILIASPA	CAVER
MI-BCAT ATRADOSTIVESTREPOANAARLESSARRIAITEELE-BELF IDSLQUIAVDNAWPRAGGEEAL/LEPPITATEEGG/WEAQURYLLIASPAGAYEK Ma-BCAT ATRADOSTIVESTREPOANAARLESSARRIAITEELE-BELF IDSLQUIAVDNAWPRAGGEEAL/LEPPITATEEGG/WEAQURYLLIASPAGAYEK Ma-BCAT ATRADOSTIVESTREPOANAARLESSARRIAITEELE-BELF IDSLQUIAVDNAWPAAGGEEAL/LEPPITATEEGG/WEAQURYLLIASPAGAYEK SC-BCAT ATREPOSTATERENARATLESSARRIAITEELE-BELF IDSLQUIAVDNAWPAAGGEEAL/LEPPITATEEGG/WEAQURE-YLLIASPAGAYEK SC-BCAT ATREPOSTATERENARATLESSARRIAITEELE-BELF IDSLQUIAVDNAWPAAGGEEAL/LEPPITATEEGG/WEAQUREYLLIASPAGAYEK SC-BCAT ATREPOSTATERENARATLESSARRIAITEELE-DET IDSLQUIAVDNAWPAAGGEEAL/LEPPITATEEGG/WEAQUREYLLIASPAGAYEK SC-BCAT ATREPOSTATIVESTATION DEMINISARVATIVEYD-KEELLECIQU/WELQUEKWP-YSTASIAITIRPAFIOTEESLG/WKR/TKALLUIASPAGAYEK SC-BCAT CYDSHKG-FWVERHREHWQLEASHIDSKITYRFV0SQSIDELMEACROVIKHOW	Mu-BCAT	ATRWADGSIVS	RAWANAARD	RSSARRMATPEL	P-FFLFIFS	LTOLIAVDNVI	WPPAGGEFAI	VI.RPETTATEPG	LCVRPAKOVE	VILLASPA	GATER
MI-BCAT ATMARDGSTUGREDAMAARLBGSARNLATEELD - ELETESLEQUIAVDNAWPPAGGEESLTYLREPVIATEPEGGVRPSARQVLLASPAGAYEK MG-BCAT AYRNADGSTUGREDAMAARLGSGARNLATEELD - ELETESLEQUIAVDEKWPPAGGEESLTYLREPVIATEPEGGVRPSARQVLLASPAGAYEK MG-BCAT AYRNADGSTUGREDAMAARLGSGARNLATEELD - ELEVETESLEQUIAVDEKWPPAGGEESLTYLREPVIATEPEGGVRPSARQVLLASPAGAYEK MG-BCAT AYRNDOSGTUGREDAMAARLGSGARNLATEELD - ELEVETESLEQUIAVDEKWPPAGGEESLTYLREPVIATEPEGGVRPSARQVLLASPAGAYEK MG-BCAT AYRDDGSTUGREDAMAARLGSGARNLATEELD - ELEVETESLEQUIAVDEKWPPAGGEESLTYLREPVIATEPEGGVRPSARQVLLASPAGAYEK BS-BCAT AYRDDGSTUGREDAMARLGSGARNLATEELD - ELEVETESLEQUIAVDEKWPPAGGEESLTYLREPVIATEPEGGVRPSARQVLLASPAGAYEK BS-BCAT CYDSHKG-PVVFRHREHMORLHDSAKTYRFVSGIDELMEACRDVTRKINLTSAYTRPLFYFVATEPESLGVKRSTAVIFVVLSEVGSYG BS-BCAT YSGUVFRLREHLWRIVESAKSTHLEIPSLDETTNIVVETTRQNKUSEGAVTIQTRGAPGRAVGQUEQCOTTAYTFVK-BYGG BS-BCAT GVLFGLREHAERFFRSARLGIGISLPSIEDETNIVVETTRQNKVSEGAVTIQTTRGVAPRKHQYEAGLEPQTTAYTFVK-B BS-DAT VYKGUVFGLREHLEPSIEDISLEPSIEDLENDIQKUQENAVSEGAVTIQTTRGVAPRKHQYEAGLEPQTTAYTFVK-BYGG MG-BCAT GG-TAPVSWWSTEYVRACPGGTG-AAFGGGNYASLLAQAEARECOQVWIDAVERKYTEEMGGMIFFVLGSGGSARLVTPELGSGLLPGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGGNYASLLAQAEARECOQVWIDAVERKYTEEMGGMIFFVLGSGGSARLVTPELGSGLLPGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGGNYASLLAQAEARECOQVWUDAVERKYEEMGGMIFFVLGKGGSARLVTPELGSGLLPGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGGNYASLLAQAEARECOQVWUDAVERRYVEEMGGMIFFVLGKGGSARLVTPELGSGLLPGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGGNYASLLAQAEARECOQVWUDAVERRYVEEMGGMIFFVLGKGGSARLVTPELGSLLFGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGGNYASLLAQAEARECOQVWUDAVERRYVEEMGGMIFFVLGKGGSARLVTPELGSLLFGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGNYASLLAQAEARECOQVWUDAVERRYVEEMGGMIFFVLGKGGSARLVTPELGSLLFGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGNYASLLAQAEARECOQVWULDAVERRYVEEMGGMIFFVLGKGGSARLVTPELGSLLFGTTRDSL MG-BCAT GG-TNPVSWWSTEYVRACPGGTG-AAFGGNYASLLAQAEARECOQVWULDAVERRYVEEMGGMIFFVLGKGGSARLVTPELGSLLFGTTRDSL MG-BCAT GG-TNPVSWWSTEYGGTG-AAFGGNYASLLAQAEARECOQVWULDAVERRYVEE	MI_BCAT	ATRWADGSIVS		DOCADDIATORI	D_DETETDS	LCOL TAVDNA	WDDVCCEENI	VI PDETENTEDC	I CUPPAKOVE		CAVER
ATWARDGS I VSEPERANARLOG SARRLA I PELP - BEVETES LEQUIA VDEWWP PAGGERS LY LREPVIA TERELGOVREN WET - L'LLAS PAGATEK SC-BCAT ATRAPGS VSTEPRENNARK QAS SARRLA I PELP - BEVETES LEQUIA VDEWWP PAGGERS LY LREPVIA TERELGOVREN MET - FIVLAS PAGATEK SC-BCAT ATRAPGS VSTEPRENNARK QAS SARRLAMELP - DET VESLEQUIA VDEWWP PAGGERS LY LREPVIA TERELGOVREN MET - FIVLAS PAGATEK SC-BCAT ATRAPGS VSTEPRENNARK QAS SARRLAMELP - DET VESLEQUIA VDEWWP PAGGERS LY LREPVIA TERELGOVREN MET - FIVLAS PAGATEK SC-BCAT CYDSHG-PVVERHERENNETS AN VALUE VDE - KEELLECIQUI VLLOQEWVP - YSTSAS LY TRE AFIGTEP SLOVKARS YN - FWILLS PVG YFS BC-BCAT CYDSHG-PVVERHERENNETS AN VALUE VDE - KEELLECIQUI VLLOQEWVP - YSTSAS LY TRE AFIGTEP SLOVKARS YN - FWILLS PVG YFS BC-BCAT CYDSHG-PVVERHERENNETS AN VALUE VDE - KEELLECIQUI VLLOQEWVP - YSTSAS LOVKARS YN - FWILLS PVG YFS BC-BCAT CYDSHG-PVVERHERENNETS AN VALUE VDE VLEDE IT NI VOET I RONK LYSAN YN PLUS SAGANLAUD PDC YN	Ma-BCAT	ATRWADGSIVS		CONTRACTOR CONTRACTOR	DELFIELES	I POT TAVDNAI	WDAACCEEAL	VI PDEVIATEDC	I CUPPSKOVE	VIIIASIV	CAVER
AVREPOSVATUSNE PROVINCE PROVIN	Ma-DCAT	AVEWADCSTUS	PDFANAADI (	ACCAPPIATET	D_FEVETES	I POI TAVDERI	WDDACCEESI	VI PDEVIATEDC	I CUDDONEVE	VIIIASPA	CAVER
ARTDOGWULTEPPONTRULARSCENSMPLD-EEL/LEALTQUVELEKMOVENSSELDUTTULATION AND THAN THE SUDVARSTYN AND THAN THE SUDVARSTYN AND THE SUD	Re-DCAT	ATRWADGSTVST	DDERNCADE	23 CODI CMDEL	D_VDTFTFA	CDALVAODERI	WDAUCCEESI	VI PDEMIATEVC	I CUPPANEVI	FIVIASPA	CAVED
ARGUNALIN LIGOPILIMBORMICAND. AND CLARANCE LID. LIDALING VIEW MANY HANGE CONTINUE VIEW AND HANGEN LIDALING VIEW AND HANGEN LIPPULGENGEN HIPPULGENGEN HIPPULGENGENGENGENGENGENGENGENGENGENGENGENGENG	Do-DCAT	ATRICIDGSVAT	PPDONTKPI	DECEDMENDEL	D_FFIVIEA	I TOI VEI EKDI	WDKEKC_TGI	VIDDEVIATEDS	L CUKASDSVI		CSVVC
Instructure       Provide the instructure <td< th=""><th>UG-DCAT</th><th>AFRIDDGRUDI</th><th></th><th>VICOCLINIONI I DUE</th><th>D BEBVIER</th><th>TOOLVELDOEL</th><th>WINERG ISL</th><th>VIDDAEICTEDS</th><th>LOVINOTVAL</th><th>- I FVI I SDV</th><th>CDVEC</th></td<>	UG-DCAT	AFRIDDGRUDI		VICOCLINIONI I DUE	D BEBVIER	TOOLVELDOEL	WINERG ISL	VIDDAEICTEDS	LOVINOTVAL	- I FVI I SDV	CDVEC
Eurocht       Cholman	RO-DCAT	CVDSHKC_DW/		UNCARTYDEDVC	OGIDEIMEN	CDDAIDKNN <sup>-</sup>	ISISASI	VIDDI TEVCOVC	MCUNDDACVS		GAVIC
Die CMV       GMV FAUGUNADIESANALIGISLPSIEDLENDLOKUVOENA	Ba-BCAT	VVSCNV	DIDEUIVOI	VESAKSTMIETD	VGIDETIMI	WETTRONK_		DI WSPCACNI C	IDDDSCTKDN		TGIED
BB-DARI       VIN       OPE GENERALMENT NUMERIZATION FOLDER PARTY CONSTRUCTION       VESSIVITY INSTRUCTION FOLDER VIEW         210       220       230       240       250       260       270       280       290       300         ME-BCAT       GG-IAPUSUWUSTEVUNACPGGTG-AAK GGNYAASLLAQAEAENCCDQVWLLDAVERYVIEEMGGMNIFFVLGSGGSARLUTPELSGSLLPGITRDSL       Mm-BCAT       GG-IAPUSUWUSTEVUNACPGGTG-AAK GGNYAASLLAQAEAENCCDQVWLLDAVERRYVEEMGGMNIFFVLGKGGSARLUTPELSGSLLPGITRDSL         MM-BCAT       GG-INPUSUWUSTEVUNACPGGTG-AAK GGNYAASLLAQAEATENCCDQVWLLDAVERRYVEEMGGMNIFFVLGKGGSARLUTPELSGSLLPGITRDSL         MM-BCAT       GG-INPUSUWUSTEVUNASPGGTG-AAK GGNYAASLLAQAEAENCCDQVWLLDAVERRYVEEMGGMNIFFVLGKGGSARLUTPELSGSLLPGITRDSL         MA-BCAT       GG-INPUSUWUSTEVUNASPGGTG-AAK GGNYAASLLAQAEAANCCDQVVULDAVERRYVEEMGGMNIFFVLGKGGSARLUTPELSGSLLPGITRDSL         MA-BCAT       GG-INPUSUWUSTEVUNASPGGTG-AAK GGNYAASLLAQAEAANCCDQVVULDAVERRYVEEWGGMNIFFVLGKGGSARLUTPELSGSLLPGITRDSL         SG-BCAT       GG-INPUSUWANAPPGGMG-DAKTGGNYAASLLAQAEAAANCCDQVVLDAVERRVEEWGGMNIFFVIGGGSARLUTPELSGSLLPGITRDSL         SG-BCAT       GG-INPUSUWANAPYGGMG-DAKTGGNYAASLLAQAEAAANCCDQVVLDAVERRVEEWGGMNIFFVIGGGSARLUTPELSGSLLPGITRDSL         SG-BCAT       GG-INPUSUWANAPANTIPTAAGGNYAASLLAQAEAAANCCDQVCULDAIERRWVEEUGGMNIFFVIGGGSARLUTPELSGSLLPGITRDSL         SG-BCAT       GG-INPUSUWANAPANTIPTAAGGNYAASLLAQAEAAANCCDQVCULDAIERRWVEEUGGMNIFFVIGGGSARLUTPELSGSLLPGITRDSL         SG-BCAT       GG-INPUSUWANGAVGGGT-FAKTGGNYAASLLAQAPCOUNCOQUULLAIENTRWEEUGGMNIFFVIGGGSARLUTPEL	Ba-DAAT	VISGNVE	CI DEUXEDEI	PROVATION D	ISLULINI RGIEDIEWD	VVETIKQNK	USECAU	VIOTTRCUARRE	HOVENCIERC	VVVIAEQ	MKK-D
210       220       230       240       250       260       270       280       290       300         Mt-BCAT       GG-IAPVSWWSTEYVRACPGGTG-AAK/GGNYAASLLAQAEAAENGCDQ/WULAVERRYIEEMGGMNIFFVLGSGGSARLVTPELSGSLLPGITRDSL         Mm-BCAT       GG-IAPVSWWSTEYVRACPGGTG-AAK/GGNYAASLLAQAEAAENGCDQ/WULAVERRYIEEMGGMNIFFVLGSGGSARLVTPELSGSLLPGITRDSL         Mm-BCAT       GG-INPVSWWSTEYVRACPGGTG-AAK/GGNYAASLLAQAEATENCCDQ/WULAVERRYVEEMGGMNIFFVLGSGGSARLVTPELSGSLLPGITRDSL         Mm-BCAT       GG-INPVSWWSTEYVRASPGGTG-AAK/GGNYAASLLAQAEATENCCDQ/WULAVERRYVEEMGGMNIFFVLGSGGSARLVTPELSGSLLPGITRDSL         Mm-BCAT       GG-INPVSWWSTEYVRASPGGTG-AAK/GGNYAASLAQAEAANCCDQ/WULAVERRYVEEMGGMNIFFVLGSGGSARLVTPELSGSLLPGITRDSL         Ms-BCAT       GG-ISPVSWUSSEVRAAPGGMG-AAK/GGNYAASLAQAEAAANCCDQ/WULAVERRYVEEMGGMNIFFVLGSGGSARLVTPELSGSLLPGITRDSL         Ms-BCAT       GG-ISPVSWUSSEVRAAPGGMG-DAK/GGNYAASLAQAEAAANCCDQ/VVLDAIERRWVEEMGGMNIFFVLGSGSARLVTPELSGSLLPGITRDSL         Ms-BCAT       DDLKPVRIVVEDEVVRAAVGGMG-PAK/GGNYAASLAQAEKAAEGYDQ/ULAJAIERWVEEMGGMNIFFVUMGGGEELAIPPLJGIILFDGTRCI         Bs-BCAT       DDLKPVRIVVEDEVVRAWKGGTG-DAK/GGNYASLAQAEKANELGYDQ/ULAJAIERWVEEMGGMNIFFVUMCGGANIFFVIGGGSARLVTPELSGSLLPGITRDSL         Bs-BCAT       DDLKPVRIVVBEWVRAWKGGTG-DAK/GGNYASLAQAEKANELGYDQU/ULDAIERWVEEMGGMNIFFVUMCGGANIFFVIGGGSARLVTPELSGSLLPGITRDSL         Bs-BCAT       DDLKPVRIVVBWYNWKGGYG-FKAAGGNYASLAQAEKANELGYDQU/ULDAIERWVEEMGGMNIFFVIGGGMTAIPLYDLSGSLLGGMNLTPENSSLLSGSILFGTRAN         Bs-BCAT       DDLKMWSSWNNAAPHTIFTAAKAGGNYLSLLUAQAEAEAANCCDQUVV	BS-DAAT	VIKGVL	GLKENAERFI	CROARLIGIOLF.	COLEDIEMD	пбип Абрич	VSEGAV	IIQIIKGVAFKK	ngiergerç	IIAIIFI	VKK-F
310       320       330       340       350       360       370       380       390         Mt-BCAT       LQLAIDAG-FAVEERRIDIDEWQKKAAAGEITEVFACGTAAVITPVARVRHGASEFRIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-         Mb-BCAT       LQLAIDAG-FAVEERRIDIDEWQKKAAAGEITEVFACGTAAVITPVARVRHGASEFRIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-         Mm-BCAT       LQLALDAG-FAVEERKIDIAEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDGEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMSRL         Mu-BCAT       LQLAIDAG-FAVEERKIDIAEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDGEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMSRL         Mu-BCAT       LQLAIDAG-FAVEERKIDIAEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDGEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMSRL         Mu-BCAT       LQLAIDAG-FAVEERKIDIDEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDGEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMSRL         Mu-BCAT       LQLAIDAG-FAVEERKIDIDEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDGEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMSRL         Ma-BCAT       LQLAIDAG-FAVEERKIDIDEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDGEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-         Ma-BCAT       LQLATDAG-FAVEERKIDDEWQKKAAAGEITEVFACGTAAVITPVSRVKYGDEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-         Ms-BCAT       LQLATDAG-FAVEERKIDDEWQKKAAGEITEVFACGTAAVITPVSRVKYGDEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-         Ms-BCAT       LQLATDAG-FAVEERKIDDEWQKKAAGEITEVFACGTAAVITPVSRVKYGDEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-         Ms-BCAT       LQLATDAG-FAVEERKIDDEWQKKAAGEITEVFACGTAAVITPVSRVKYGDEFTIADGQPG-EVTMALRDTLTGIQRGTFADTHGWMARLG-	Mt-BCAT Mb-BCAT Mu-BCAT Mu-BCAT Ma-BCAT Ms-BCAT Ms-BCAT Bs-BCAT Bs-BCAT Ba-BCAT Bs-DAAT	GG-IAPVSVWVS GG-IAPVSVWVS GG-INPVSVWVS GG-INPVSVWVS GG-ISPVTVWVS GG-IFVVSVWVS GG-VFVSIWVS DDQLKPVRIVVS SGTFNPVSLWAN AEALEQGIDAM QEYYEKGIPVV1 EQEQAYGVAAI1	STEYVRACPG STEYVRACPG STEYVRACPG STDYVRACPG STDYVRACPG STEYVRASPG SEEYVRASPG SEDRVRAVPG SEDRVRAVNG SEDRVRAVNG SEDRVRAVNG SSWNRAAPN VATRRNRPD TEDLR	GTG-AAKFGGNY, GTG-AAKFGGNY, GTG-AAKFGGNY, GTG-AAKFGGNY, GTG-AAKFGGNY, GTG-AAKFGGNY, GTG-AAKFGGNY, GTG-DAKTGGNY, GTG-DCKMGGNY, TIPTAAKAGGNY, VLSPQVKS-LNY, WLRCDIKS-LNL	AASILAQAE AASILAQAE AASILAQAE AASILAQAE AASILAQAE AASILAQAE AASILAQAE AASILAQAE AASIQAQRK GSSLFAQCE LSSLLVGSE LNNILVRIE LYNVMTKQR	AAENGCDQVVI AAENGCDQVVI AAENGCDQVVI ATENGCDQVVI AAENGCDQVVI AAANGCDQVVI AAANGCDQVVI AAELGYDQVLI ARELGYDQVLI ARELGYDQVLI ARHGYQEGI AKLAGVQEA AYEAGAFEA	WIDAVERRYIE WIDAVERRYIE WIDAVERRYVE WIDAVERRYVE WIDAVERRYVE WIDAUERRYVE WIDAIERRYVE WIDAIERKYVE WIDAIEKKYVE WIDAIEKKYVE WIDAIEKKYVE WIDAIEKKYVE WIDAIEKYVE WIDAIEKYVE WIDAIEKYVE WIDAIEKYVE WIDAIEKYVE WIDAIERYVE	DEMGGMNIFFVLG DEMGGMNIFFVLG DEMGGMNIFFVLG DEMGGMNIFFVLG DEMGGMNIFFVLG DEMGGMNLFFVFG DELGGMNLFFVFG DELGGMNLFFVFW DEGAGENLFEVKD DEGGSDNVFIVKG DEGSDNVFIVKG	SGGSARLVTF SGGSARLVTF KGGSARLVTF SGGSARLVTF SGGSARLVTF SGGSARLVTF GGCEELATF GVLFTF NKLTFF GVLFTF GTVRTF	ELSGSLLPGI ELSGSLLPGI ELSGSLLPGI ELSGSLLPGI ELSGSLLPGI ELSGSLLPGI ELSGSLLPGI SLTGSILEGV ALSGSILSGV PLDGIILPGV PFTSSALPGI PSSAGALEGI IPANRLILNGI	TRDSL TRDSL TRDSL TRDSL TRDSL TRDSL TRDSL TRDSL TRDSL TRASA TRRCI TRDAI TRNAI TRNAI
Ba-BCAT         LEIGEKLG-YDVREELFTRHDVYVADEVFLTGTAAEVIAVTTVDGRTIGLGQTG-PHTNRLLEEFRKLVIEDGEKIYEENKVG           Bs-DAAT         LGLIEKNG-IKLDETPVSEEELKQAEEIFISSTTAEIIPVVTLDGQSIGSGKPG-PVTKQLQAAFQESIQQAASIS	Mt-BCAT Mm-BCAT Mm-BCAT M1-BCAT M1-BCAT Ma-BCAT Ms-BCAT Sc-BCAT BS-BCAT HS-BCAT Ec-BCAT	310 LQLAIDAG-FA\ LQLAIDAG-FA\ LQLALDAG-FA\ LQLALDAG-FA\ LQLAIDAG-FA\ LQLAIDAG-FS\ LQLAIDAG-FA\ LQLAIDAG-FA\ LTVARDLG-YEZ IELIRSWG-IP\ LDLAHQWGEFK\ IKLAKELG-IE\	320 VEERRIDIDEU VEERRIDIDEU VEERKIDIAEU VEERKIDIDEU VEERKIDIDEU VEERKIDIDEU VEERKIDIDEU VEERKIDIDEU VEERRIDIDEU VEERRIDIDEU VSERVILTMDDI VREQVLSRESI	330 WQKKAAAGEITE WQKKATAGEITE WQKKATAGEITE WQKKAAAGEITE WQKKAAAGEITE WQRXSAGAGEITE WQRDSENGTLTE VYAASARGEITE LTTALEGNRVREI LYLADE	340 VFACGTAAV VFACGTAAV VFACGTAAV VFACGTAAV VFACGTAAV VFACGTAAV VFACGTAAV VFACGTAAV VFGTGTAAV MFSSGTACV	350 ITPVARVRHGJ ITPVARVRHGJ ITPVSRVKYGI ITPVSRVKYGI ITPVSRVKYGI ITPVSRVKHHI ITPVGTVKRAC VTPVGELNIHC VCPVSDILYKC ITPVRSVDG	360 ASEFRIADGQE ASEFRIADGQE DGEFTIADGQE DGEFTIADGQE DGEFTIADGQE STEFTIADGQE SAQWQQSGET SKTVIVGDGQI GETIHIPTMEN IQVGEGRC	370 G-EVTMALRDTL G-EVTMALRDTL G-EVTMALRDTL G-EVTMALRDTL G-EVTMALRDTL G-EVTMALRDTL G-EVTMALRDTL G-EVTQRLRDAL G-EVTQRLRDAL G-DLSKKLYETI GPKLASRILSKL G-PVTKRIQQAF	380 TGIQRGTFAL TGIQRGTFAL TGIQRGTFAL TGIQRGTFAL TGIQRGTFAL TGIQRGTFAL DIQRGTFAL DIQRGTVAL TDIQLGKVKG TDIQLGKVKG TDIQYGRE FGLFTGETEL	390 THGWMARLG- THGWMARLG- THGWMSRL THGWMSRL THGWMARLG- THGWMARLG- THGWMARLG- PHGWMHTLA- PHGWMHTLA- SPFNWTVEV ESDWTIVLS- KWGWLDQVNQ	
	Ba-BCAT Bs-DAAT	LEIGEKLG-YDV LGLIEKNG-IKI	REELFTRHDV DETPVSEEE1	VYVADE LKQAEE	VFLTGTAAE IFISSTTAE	VIAVTTVDGR- IIPVVTLDGQ-	TIGL <mark>G</mark> QT SIGS <mark>G</mark> KP	G-PHTNRLLEEF G-PVTKQLQAAF	RKLVIEDGEK QESIQQAASI	IYEENKVG S	

Alignment of selected family III aminotransferases. The following sequences were aligned with the Clustal algorithm: Mt-BCAT, M. tuberculosis BCAT [23]; Mb-BCAT, M. bovis BCAT [51]; Mm-BCAT, M. marinum BCAT; Mu-BCAT, M. ulcerans BCAT; MI-BCAT, M. leprae BCAT [52]; Ma-BCAT, M. avium BCAT; Ms- BCAT, M. smegmatis BCAT; Sc- BCAT, Streptomyces coelicolor BCAT [53]; Bs-BCAT, Bacillus subtilis BCAT YbgE [43]; Hs-BCATI, human BCATI [54]; Ec-BCAT, Escherichia coli BCAT IIvE [55]; Ba-BCAT, B. anthracis BCAT2 [16]; Bs-DAAT, B. subtilis DAAT YheM [43]). Residues conserved by 80% of the sequences are shown in blue. The boxed residues represent the pyridoxal-5-phosphate binding site.

M P S F W E

**Purification of recombinant M. tuberculosis BCAT.** *E. coli* BL21(DE3) CodonPlus-RIL cells were induced with IPTG and prepared as described in the Materials and Methods section. The cell lysate was separated by centrifugation into pellet (P) and supernatant (S) fractions. The supernatant was loaded onto an Ni<sup>2+</sup>-charged metal ion affinity column and flow through (F), 80 mM imidazole (W), and 800 mM imidazole (E) fractions were collected. Aliquots of each fraction were analysed on a 10% polyacrylamide gel under reducing conditions. Lane (M) contains molecular mass markers (units in kDa).

– 2.85 mM, while that for Glu was 9.53 mM and Phe 7.44 mM. The Vmax for all five amino acids was similar at 2.17 – 5.70 µmol/min/mg protein. KMTB was found to have a Km of 4.20 mM. The enzyme was also examined for branched-chain amino acid and KG aminotransfer in order characterise the "classic" reactions associated with a BCAT (Table 1). The Km of the substrates was found to be similar, while the Vmax ranged from 11.82 – 14.35 µmol/min/mg protein. Therefore, the tuberculosis BCAT catalyses aminotransfer of KG about 3 times more readily than KMTB. This result is similar to that seen with the *B. subtilis* BCAT, which also transaminates KG at a higher rate than KMTB [16].

### Inhibition studies

Thirteen aminooxy compounds were assayed for inhibitory effects on the tuberculosis BCAT. The enzyme was incubated with 2.0 mM leucine, 1.0 mM KMTB and 0.1 or 1.0 mM inhibitor to assay for the effect on Met regeneration (Figure 6). With the exception of O-trimethylsilylhydroxylamine, all of the compounds inhibited Met formation to some extent. The four most active compounds at 0.1 mM were O-allylhydroxylamine, carboxymethoxylamine, O-benzylhydroxylamine, and O-tbutylhydroxylamine, and these inhibitors were further examined in order to determine  $K_i$  values (Table 2). For all four compounds, the inhibition data was not consistent with a simple competitive or uncompetitive model, but fit very well with a model of mixed mode inhibition [25]. The competitive component of inhibition yielded a  $K_{ic}$  of 8.20 – 21.61  $\mu$ M, while the uncompetitive component gave a  $K_{iu}$  of 84.08 – 386  $\mu$ M. Therefore, the inhibition of the tuberculosis BCAT by these four aminooxy compounds is primarily competitive.

These four inhibitors and canaline, an aminooxy analogue of ornithine that has been demonstrated to be an effective aminotransferase inhibitor in other systems [16,17,26-28], were screened against M. tuberculosis and M. marinum in vitro to determine potential antimicrobial activity. M. marinum is a close relative of M. tuberculosis that causes a similar disease in fish, grows faster than M. tuberculosis in culture, and does not cause serious infections in humans [29]. As such, it is an excellent surrogate for the initial screening of antimycobacterial agents, and we wished to validate its use for aminooxy compounds. All the inhibitors were found to have some degree of antimycobacterial activity (Table 3), with MIC values ranging from 78  $\mu$ M – 10 mM and IC<sub>50</sub> values of 8.49  $\mu$ M - 467 µM. The best inhibitor was found to be O-allylhydroxylamine. While O-t-butylhydroxylamine and O-benzylhydroxylamine appeared to be the best enzyme inhibitors, they were significantly less effective than Oallylhydroxylamine as growth inhibitors. Unlike other organisms examined to date [27,30], canaline was not a particularly good inhibitor of both enzyme activity and cell growth. The inhibition results for M. tuberculosis and M. marinum were very similar, with MIC results being identical or within 1 dilution. In addition, M. tuberculosis was found to have an MIC of 2 µg/ml for streptomycin while M. marinum had one of 8 µg/ml.

### Discussion

The specific aminotransferase involved in the formation of Met from KMTB has been examined in a number of eukaryotic and prokaryotic organisms [7,16,17]. However, within the low-GC content Gram-positive bacteria, only *B. subtilis*, *B. cereus*, and *B. anthracis* have been studied [16]. In all of these *Bacillus spp.*, a BCAT has been found to be responsible for catalysing the reaction, with *B. subtilis* and *B. cereus/B. anthracis* utilising enzymes from different aminotransferase subfamilies. No member of the high-GC content Gram-positive bacteria has been previously examined. Like *B. subtilis*, *M. tuberculosis* has been found to catalyse Met regeneration using a subfamily IIIa aminotransferase. In fact, the kinetic parameters for the two aminotransferases were almost identical. The *M*.



The amino donor range for Met formation. The enzyme was mixed with 1.0 mM KMTB, 2.0 mM of an individual amino acid, and PLP for 30 min at 37°C before HPLC analysis of Met production.

Substrate	Cosubstrate	Apparent Km (mM)	Apparent Vmax (μmol/min/mg protein)
Leu	КМТВ	2.50 ± 0.90	3.65 ± 0.43
Val	КМТВ	1.77 ± 0.86	2.58 ± 0.41
lle	КМТВ	2.85 ± 0.56	4.28 ± 0.32
Glu	КМТВ	9.53 ± 3.43	5.70 ± 1.20
Phe	КМТВ	7.44 ± 1.40	2.17 ± 0.22
КМТВ	Leu	4.20 ± 1.79	4.22 ± 0.72
Leu	KG	6.02 ± 0.94	13.44 ± 0.84
Val	KG	5.79 ± 0.99	11.82 ± 0.80
lle	KG	6.16 ± 1.14	14.35 ± 1.08
KG	Leu	6.95 ± 1.44	12.80 ± 1.12

Table I: Kinetic characterization of *M. tuberculosis* branched-chain aminotransferase. The enzyme was incubated with varying concentrations of substrate and 10 mM cosubstrate, as described in the Methods section.

*tuberculosis* BCAT had Km values of 1.77 - 2.85 mM and Vmax values of  $2.58 - 4.28 \ \mu mol/min/mg$  protein for branched-chain amino acids and KMTB, while the *B. sub-tilis* YbgE had the corresponding values of 2.36 - 3.20 mM and  $1.84 - 2.03 \ \mu mol/min/mg$  protein [16]. For branched-chain amino acids and KG, the values were 5.79 - 6.16 mM and  $11.82 - 14.35 \ \mu mol/min/mg$  protein for the *M. tuberculosis* BCAT, and 2.82 - 3.99 mM and  $13.93 - 16.61 \ \mu mol/min/mg$  protein for *B. subtilis* YbgE [16]. Therefore, a 45% sequence identity between the two enzymes is sufficient to conserve both the substrate range and kinetic properties of the BCATs. Structural information is only available for the *E. coli* BCAT (IlvE) and the human mitochondrial BCAT [24,24,31], but the key resi-

dues involved in substrate specificity appear to be conserved in the *M. tuberculosis* BCAT. However, while the human mitochondrial BCAT is also a family IIIa aminotransferase, there are some clear differences when compared to the *M. tuberculosis* enzyme. The human enzyme will not accept aromatic amino acids, whereas the tuberculosis BCAT would use phenylalanine as an amino donor. In addition, the human enzyme contains the redox-active motif CXXC at positions 311–314 (positions 341–344 in Figure 3) which is essential for maintaining activity, while the tuberculosis BCAT lacks these residues. Structural analysis of the *M. tuberculosis* and/or *B. subtilis* enzymes would clarify these issues.



**Inhibition of branched-chain aminotransferase by aminooxy compounds.** Leucine, KMTB, PLP and I mM (black bars) or 0.1 mM (white bars) of inhibitor were incubated with Mt-BCAT as described in the Methods section. Percent activity is shown relative to a positive control which contained no inhibitor.

Table 2: Ki determination for selected aminooxy inhibitors. The enzyme was incubated with variable amounts of leucine and inhibitor and fixed amounts of KMTB, as described in the Methods section. Kic and Kiu refer to the competitive and uncompetitive components of mixed-type inhibition [25].

Inhibitor	Kic(μM)	Kiu(μ <b>M</b> )
O-(t-butyl)hydroxylamine	11.02 ± 2.76	85.60 ± 44.79
carboxymethoxylamine	20.97 ± 7.27	142.42 ± 69.76
O-allylhydroxylamine	21.61 ± 11.08	>200 (386)*
O-benzylhydroxylamine	8.20 ± 2.56	84.08 ± 31.91

\*200 μM was the highest concentration of inhibitor tested in these experiments. The calculated Kiu value is shown in parentheses.

The *M. tuberculosis* BCAT was also screened with a variety of aminooxy compounds as potential inhibitors. These compounds are known aminotransferase inhibitors and act by forming a stable Schiff-base with the PLP cofactor [32]. Unlike previous studies [7,16,17,33], canaline was not found to be one of the better inhibitors of aminotransferase activity. Instead, O-benzylhydroxylamine,

O-t-butylhydroxylamine, carboxymethoxylamine, and Oallylhydroxylamine were the most efficient inhibitors of Met formation from KMTB. In addition, these compounds demonstrated mixed type inhibition with a lower Ki for the competitive component. This result contrasts with that previously found for canaline with the *Bacillus spp*. enzymes, where inhibition was uncompetitive [16]. It

Table 3: In vitro growth inhibition of M tuberculosis and M. marinum by aminooxy compounds. One hundred $\mu$ L of a mid-logarithmic
culture of M. tuberculosis or M. marinum at a concentration of 2 × 10 <sup>5</sup> cfu/ml was added to 100 $\mu$ L of serial doubling dilutions of inhibitor
in a 96-well microtitre plate. The drug plates were grown for 14 days at 37°C (M. tuberculosis) or 8 days at 30°C (M. marinum) with no
agitation before checking for cell growth at A <sub>650 nm</sub> . The minimum inhibitory concentration (MIC) and inhibitory concentration 50%
(IC50) were calculated as described in the Methods section.

Inhibitor	M. marinum (n = 8)		M. tuberculosis (n = $0$	M. tuberculosis (n = 6)		
	MIC (mM)	IC50 (μM)	MIC (mM)	IC50 (μM)		
0-allylhydroxylamine	0.078	8.49 ± 1.96	0.156	39.22 ± 2.01		
carboxymethoxylamine	0.313	89.32 ± 7.65	0.313	70.99 ± 7.83		
O-benzylhydroxylamine	1.25	410.76 ± 67.10	1.25	467.54 ± 62.80		
canaline	1.25	335.29 ± 13.64	1.25	273.18 ± 14.64		
0-(t-butyl)hydroxylamine	10	43.18 ± 10.51	10	130.52 ± 23.10		

may be possible that this difference may be due to the structure of the inhibitors, as canaline is a  $\gamma$ -substituted amino acid analogue, while the present inhibitors are  $\alpha$ -substituted or non-amino acid analogues. Essentially, the inhibitors examined in this study do not present an  $\alpha$ -amino group suitable for participation in the transamination reaction whereas canaline does.

Further screening of the inhibitors against *M. tuberculosis* and *M. marinum* in vitro demonstrated that the compounds can act as effective antimycobacterial agents. The close correspondence of the MIC values for *M. tuberculosis* and *M. marinum* validates the use of the latter organism as a more rapid and safe initial screen of the antimycobacterial properties of aminooxy compounds. The MIC values found for streptomycin against these two organisms was also found to be consistent with previously published values [34]. *M. marinum* can thus be used to quickly test a larger number of potential inhibitors, with *M. tuberculosis* used as a follow up for more promising candidates.

Interestingly, there was no direct correlation between the Ki of the compounds against recombinant *M. tuberculosis* BCAT and the MIC/IC<sub>50</sub> against cell growth. It is possible that there may be differences in the uptake rate of the various compounds into viable cells. Alternatively, the most effective growth inhibitors act by inhibiting other PLP-dependent enzymes in addition to BCAT. In any case, O-allylhydroxylamine was the most effective antimycobacterial agent with an MIC of 78  $\mu$ M against *M. marinum* and 156  $\mu$ M against *M. tuberculosis*. Unfortunately, the compound is corrosive, and is thus unsuitable for further in vivo study. However, the structure of the compound might provide the basis for the design of less toxic, more active structural analogues. In future studies, it will be necessary to examine the effect of potential inhibitors on

human BCAT, in order to better assess the potential for host toxicity. Any further development of aminooxy compounds as antimycobacterial agents will depend on discovering a selective inhibitor for the microbial enzyme.

Several older studies have been conducted on the antimicrobial effect of aminooxy compounds, with M. tuberculosis included amongst the organisms tested [35-39]. From these papers, the only compound in common with the present study was carboxymethoxylamine, which was found to have an MIC of 313 µM (present data), 910 µM [35], 170 – 686 µM [36], or 170 µM [37]. Given the variety of media used in these studies for determining the MIC value, the results are quite consistent. The variety of noncommercially available aminooxy compounds synthesized and tested in these older studies included aminooxy acids, aminooxy amides, aminooxy hydroxamic acids, aminooxy hydrazides, aminooxy alkanes, and aminooxy guanidines. Several of these compounds were very effective growth inhibitors in vitro, with MIC values as low as 0.30 µM against M. tuberculosis. One of the compounds has been administered to mice, with favourable, albeit sparsely detailed, results with regard to toxicity and in vivo antitubercular effect [38]. While it is unclear what effect these inhibitors would have against the M. tuberculosis BCAT, it would appear to be possible to design more effective, less toxic aminooxy compounds for use against M. tuberculosis.

Several interesting findings arose during the course of this investigation. First, while *M. tuberculosis* has only the one branched-chain aminotransferase, it does contain a cod-ing sequence (Rv0858c) with a high similarity to the *B. subtilis* ykrV gene product. YkrV was found to be a subfamily If aminotransferase and could also catalyse the conversion of KMTB to Met using glutamine as the only effective amino donor [16]. Therefore, it is possible that

the Rv0858c gene product might be capable of KMTB transamination. It should be stressed that while the recombinant *B. subtilis* YkrV could transaminate KMTB with glutamine, *B. subtilis* cell homogenates did not produce Met from KMTB when supplemented with glutamine [16]. Similarly, cell homogenates of *M. smegmatis* grown in Middlebrook 7H9 incomplete medium were only able to produce Met from KMTB when supplemented with valine, isoleucine, leucine, glutamate, or phenylalanine, as was seen for the recombinant *M. tuberculosis* BCAT in figure 5 (data not shown).

*M. tuberculosis* was found to contain no putative gene product with significant homology to a DAAT. In fact, the organism appeared to contain no subfamily IIIb aminotransferases. The physiological significance of a lack of a DAAT is unclear, but many organisms do not contain a homologue of this enzyme. With DAAT, there might be a diminished capacity to catabolise D-amino acids for energy, although the same reactions could be performed by a D-amino acid oxidase. *M. tuberculosis* is known to be reliant on carbohydrate catabolism during the active growth phase and lipid metabolism during the chronic, dormant phase [40]. Therefore, the lack of a DAAT might be reflective of a lifestyle where protein and peptide catabolism is relatively unimportant.

Similarly, M. tuberculosis was found to lack clearly identifiable homologues of several enzymes in the Met regeneration pathway. The most glaring omission is the lack of an S-adenosylmethionine decarboxylase (SAMdc) homologue (see Figure 1). M. tuberculosis contains the preceding enzyme, methionine adenosyltransferase [21], and has an easily identifiable homologue for the succeeding enzyme, spermidine synthase [23]. Therefore, M. tuberculosis must catalyse SAMdc activity via another enzyme in order to be able to synthesize polyamines. A previous study has demonstrated SAMdc activity in M. bovis homogenates, but has not identified the enzyme responsible [41]. Resolution of this issue is critical for a more complete understanding of polyamine biosynthesis in tuberculosis, and may yield a novel enzyme as an additional drug target. The M. tuberculosis genome also appears to be missing homologues of the enzymes converting methylthioribose to KMTB (see Figure 1). However, outside of K. pneumoniae and B. subtilis, these enzymes have not been well studied, and, between these two organisms, there are key differences in the enzymes catalyzing several steps [12,20]. In silico analyses have suggested that Pseduomonas aeruginosa, Xylella fastidiosa, Leptospira interrogans, and Thermoanaerobacter tengcongensis have readily identifiable, complete Met regeneration pathways [42]. However, the presence or absence of the pathway in a variety of prokaryotic and eukaryotic organisms remains to be determined by functional analysis. Therefore, there is much left to examine before concluding that *M. tuberculosis* contains neither homologues nor analogues to these Met recycling enzymes. However, even in the absence of a complete Met salvage pathway, *M. tuberculosis*, as an intracellular pathogen, might utilise exogenous KMTB as a Met source.

## Conclusions

Branched-chain amino acid aminotransferase has been cloned and characterised from *M. tuberculosis*. This enzyme was found to be responsible for the formation of methionine from ketomethiobutyrate, and could be inhibited in vitro by a series of aminooxy compounds. Several of these compounds were found to be effective inhibitors of *M. tuberculosis* or *M. marinum* growth in culture, with MIC values as low as 156  $\mu$ M and 78  $\mu$ M respectively. These studies demonstrate the importance branched-chain amino acid and methionine metabolism to the survival of mycobacteria, and open up the potential for the development of more potent and less toxic aminooxy inhibitors of the branched-chain aminotransferase.

# Methods

## Cells and reagents

*M. tuberculosis* H37Rv and *M. marinum* Aronson (ATCC927) were cultured in liquid Middlebrook 7H9 complete medium or on Middlebrook 7H10 plates at 37°C for *M. tuberculosis* or 30°C for *M. marinum*. All substrates and inhibitors were obtained from Sigma-Aldrich (Oakville, ON, Canada).

# Cloning and functional expression

Genomic DNA was isolated from *M. tuberculosis* by vortexing packed cells in a minimal volume of 50 mM Tris-HCl pH 8.0/10 mM EDTA/100 mM NaCl containing 500 µm acid washed glass beads (Sigma). After allowing the glass beads to settle, the supernatant was added to an equal volume of 10 mM Tris-HCl pH 8.0/100 mM NaCl/25 mM EDTA/0.5% w/v sodium dodecyl sulfate/0.1 mg/ml proteinase K and incubated for 1 hr at 37 °C with occasional gentle mixing. The mixture was then subjected to extraction with phenol:chloroform:isoamyl alcohol (25:24:1), and the DNA ethanol precipitated.

The sequence of the putative *M. tuberculosis* BCAT gene was discovered by a BLAST search of the complete *M. tuberculosis* H37Rv genome using the *B. subtilis* YbgE, YwaA, or YheM gene products as the query proteins [16,23,43]. The single resulting putative BCAT gene was used to construct oligonucleotide primers for PCR amplification. The 5' primer was TCGAGGCGGCCGCAAAT-GACCAGCGGCTCCCTTCA and incorporated a NotI restriction site and an in-frame start codon. The 3' primer was ATCGAGCTCGAGTTACCCCAGCCGCCGCATCCAG and incorporated a XhoI restriction site and an in-frame stop codon. The BCAT gene was then amplified using a

5:1 mixture of Taq:Pfu polymerases (Promega; Madison, WI, USA) and the following program: 1 cycle of 95°C for 1.5 min; 30 cycles of 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min; and 1 cycle of 72°C for 10 min. The resulting PCR product was excised from a 1% agarose gel and recovered using the Qiaex II kit (Qiagen; Mississauga, ON, Canada). The purified product was digested with NotI and XhoI and ligated into a similarly digested pET 19 m (a modification by us of pET19b (Novagen; Madison, WI, USA) to incorporate extra restriction sites in the multiple cloning site) using a Rapid Ligation kit (Fermentas; Burlington, ON, Canada). The recombinant plasmid was then transformed into Escherichia coli XL10 cells (Stratagene; La Jolla, CA, USA) and was subsequently recovered using the Qiaspin miniprep kit (Qiagen). Positive clones were determined by digesting the plasmid with NotI and XhoI to confirm the presence of the insert on a 1% agarose gel. The sequence of the insert was confirmed by using the Big-Dye cycle sequencing kit (ABI; Foster City, CA, USA) and an ABI Prism 310 genetic analyser.

The plasmid from positive clones was transformed into *E. coli* BL21(DE3) CodonPlus RIL cells (Stratagene) for functional expression. Cells were grown in liquid LB medium containing 50  $\mu$ g/ml ampicillin and 50  $\mu$ g/ml chloramphenicol at 37°C and 250 rpm until the culture reached an A<sub>600 nm</sub> of 0.6–0.8. The culture was then cooled to 20°C for 30 min at 250 rpm before the addition of 0.1 mM isopropylthiogalactopyranoside (IPTG) and an additional 20 hr of incubation at 20°C and 250 rpm.

The culture was centrifuged at 3500 × g for 20 min at 4°C, and the cell pellet resuspended in 50 mM HEPES (pH 7.4)/750 mM NaCl and frozen at -20°C. The resuspended cells were then thawed, sonicated on ice, centrifuged at  $3000 \times g$  for 20 min at 4°C, and the supernatant loaded onto a 1.6 × 9.5 Chelating-Sepharose-FF column (Amersham Biosciences; Baie d'Urfe, QC, Canada) charged with NiSO<sub>4</sub>. The column was washed with 50 mM HEPES (pH 7.4)/750 mM NaCl and 50 mM HEPES (pH 7.4)/750 mM NaCl/80 mM imidazole, before elution with 50 mM HEPES (pH 7.4)/750 mM NaCl/800 mM imidazole. Fractions containing the recombinant protein were pooled and concentrated to less than 3.0 ml using a 30 kDa molecular mass cut-off filter (Pall Filtron; Mississauga, ON, Canada). The concentrated enzyme was then dialysed against 50 mM HEPES (pH 7.4)/1 mM dithiothreitol/1 mM EDTA/trace pyridoxal-5-phosphate (PLP) overnight at 4°C. The concentrated enzymes were stored at 4°C for several days, or with 20% v/v glycerol at -20°C for several weeks, without appreciable loss of activity. Recombinant protein samples were examined by electrophoresis on 10% SDS polyacrylamide gels followed by Coomassie Brilliant Blue R250 staining. Protein

concentration was measured using the Bio-Rad reagent (Bio-Rad; Mississauga, ON, Canada).

## Enzyme assays and inhibition studies

Aminotransferase activities were assayed by an HPLC method [17]. 5 or 10 µl of recombinant enzyme was added to 100  $\mu$ l of substrate mix (100 mM PO<sub>4</sub> (pH 7.4)/ 50 µM PLP/various concentrations of amino acid/various concentrations of keto acid) and incubated for 30 min at 37°C. The samples were then stored at -20°C until analysis by HPLC. All samples were analysed by pre-column derivatisation and reverse-phase HPLC. 10 µl of sample was mixed with 50 µl of 400 mM borate pH 10.5 and then with 10 µl of 10 mg/ml o-phthalaldehvde/12 µl/ml mercaptopropionate/400 mM borate pH 10.5 prior to the injection of 7.0 µl onto a 2.1 × 200 mm ODS-AA column (Agilent; Mississauga, ON, Canada). The column was eluted using 2.72 mg/ml sodium acetate pH 7.2/0.018% v/v triethylamine/0.3% v/v tetrahydrofuran as Buffer A and 2.72 mg/ml sodium acetate pH 7.2/40% v/v methanol/40% v/v acetonitrile as Buffer B with a linear gradient of 0 – 17% B over 16 min followed by a linear gradient of 17-100% B over 1 min and 6.0 min at 100% B. The flow rate was 0.45 ml/min from 0 - 16 min and 0.80 ml/min from 17-30 min. The elution of derivatised amino acids was monitored at 338 nm and fluorometrically with an excitation of 338 nm and an emission of 450 nm. All separations were performed on an Agilent 1100 HPLC equipped with an autosampler, variable wavelength ultraviolet/visible spectrophotometric detector, fluorescence detector, and Chemstation operating system.

The amino donor range for Met regeneration was determined by incubating 2 mM of each individual amino acid and 1 mM KMTB, followed by HPLC for Met quantification. Amino acids which were effective amino donors were further studied at 0.1 – 10 mM amino acid and 10 mM KMTB to determine the kinetic constants. Similar assays were performed with 0.1 – 10 mM KMTB and 10 mM Leu. Replacement of KMTB with ketoglutarate (KG) in these experiments and subsequent HPLC analysis of Glu formation allowed for the determination of BCAT activity. The apparent Km and Vmax values for each substrate were assessed by non-linear curve fitting using the Scientist software programmed with the Michaelis-Menton equation (Micromath; Salt Lake City, UT, USA).

Initial inhibition studies screened 13 aminooxy compounds against *M. tuberculosis* BCAT using 2.0 mM Leu/ 1.0 mM KMTB/0.1 or 1.0 mM inhibitor in the enzyme incubation. Inhibitors which demonstrated better than 50% reduction of activity at the 0.1 mM concentration were further studied for the determination of  $K_i$  values. These reactions involved 0.5, 1.0, 2.0, or 3.0 mM Leu and 1.0 mM KMTB in the reaction mixture together with 0, 25,

50, 75, 100, 150, 200  $\mu$ M of inhibitor. The K<sub>i</sub> values were determined by non-linear curve fitting with the Scientist software programmed with competitive, uncompetitive, and mixed inhibition equations [25].

In vitro growth inhibition studies were performed on M. tuberculosis and M. marinum using the most effective enzyme inhibitors. Cultures at mid-log growth in Middlebrook 7H9 complete medium was diluted to  $2 \times 10^5$  cfu/ ml and 100 µl added to 96 well microtitre plates containing 100 µl of doubling dilutions of each inhibitor. The final inhibitor concentration ranged from 10 mM - 298 pM. Positive and negative controls consisted of 100 µl Middlebrook 7H9 medium replacing the inhibitor or cells respectively. The plates were incubated at 30°C for 8 days (M. marinum) or 37°C for 14 days (M. tuberculosis) with no agitation before measurement of growth at A<sub>650 nm</sub> using a Molecular Devices 96-well spectrophotometer (Sunnyvale, CA, USA). The MIC was determined as the lowest dilution that completely prevented microbial growth and the IC<sub>50</sub> was determined by non-linear curve fitting with the Scientist software programmed with the Chou equation [44].

#### **Phylogenetic analysis**

Additional BCAT and DAAT sequences were obtained from GenBank http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?db=Protein[38]. Mycobacterium spp. BCAT sequences from preliminary genome projects were made available from The Institute for Genomic Research http:// www.tigr.org for M. smegmatis and M. avium, from The Sanger Centre http://www.sanger.ac.uk for M. marinum, and from The Institut Pasteur http://www.pasteur.fr for M. ulcerans. These sequences were aligned using the Clustal algorithm and the BLOSUM sequence substitution table in the ClustalX program [46]. Aligned sequences were viewed using the Bioedit program [47] and were then used with the ProtDist component of the PHYLIP [48] to construct a distance matrix that was the basis for tree construction using the neighbour-joining method [49]. All trees were visualised using Treeview [50].

#### **Authors' contributions**

ESV performed the cloning, expression, and characterisation of the enzyme, and assisted in writing the manuscript. CLR assisted in the cloning and expression experiments. MHK performed the *M. marinum* experiments. BJB conceived the study, performed the *M. tuberculosis* experiments, and wrote the manuscript.

#### **Acknowledgements**

This work was funded in part by a Defence R&D Canada Technology Innovation Fund award. The authors would like to acknowledge the assistance of the University of British Columbia Science Co-op Program. Preliminary genome data was made available from The Institute for Genomic Research <u>http://www.tigr.org</u> for *Mycobacterium smegmatis* (funded by NIAID) and *Mycobacterium avium* (funded by NIAID), The Sanger Centre <u>http://www.sanger.ac.uk</u> for *Mycobacterium marinum* (funded by Beowulf Genomics), and The Institut Pasteur <u>http://www.pasteur.fr</u> for *Mycobacterium ulcerans* (funded by the Association Raoul Follereau and WHO).

#### References

- Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282:677-86.
- Gianotti AJ, Tower PA, Sheley JH, Conte PA, Spiro C, Ferro AJ, Fitchen JH, Riscoe MK: Selective killing of Klebsiella pneumoniae by 5- trifluoromethylthioribose. Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase. J Biol Chem 1990, 265:831-7.
- 3. Marton LJ, Pegg AE: Polyamines as targets for therapeutic intervention. Ann Rev Pharmacoland Toxicol 1995, 35:55-91.
- Sufrin JR, Meshnick SR, Spiess AJ, Garofalo-Hannan J, Pan XQ, Bacchi CJ: Methionine recycling pathways and antimalarial drug design. Antimicrob Agents Chemother 1995, 39:2511-5.
- Cornell KA, Winter RW, Tower PA, Riscoe MK: Affinity purification of 5-methylthioribose kinase and 5- methylthioadenosine/S-adenosylhomocysteine nucleosidase from Klebsiella pneumoniae. Biochem J 1996, 317:285-90.
- Furfine ES, Abeles RH: Intermediates in the conversion of 5'-Smethylthioadenosine to methionine in Klebsiella pneumoniae. J Biol Chem 1988, 263:9598-606.
- Heilbronn J, Wilson J, Berger BJ: Tyrosine aminotransferase catalyzes the final step of methionine recycling in *Klebsiella pneumoniae*. J Bacteriol 1999, 181:1739-47.
   Myers RW, Wray JW, Fish S, Abeles RH: Purification and charac-
- Myers RW, Wray JW, Fish S, Abeles RH: Purification and characterization of an enzyme involved in oxidative carbon-carbon bond cleavage reactions in the methionine salvage pathway of Klebsiella pneumoniae. J Biol Chem 1993, 268:24785-91.
- Trackman PC, Abeles RH: Methionine synthesis from 5'-S-Methylthioadenosine. Resolution of enzyme activities and identification of 1-phospho-5-S methylthioribulose. J Biol Chem 1983, 258:6717-20.
- Wray JW, Abeles RH: A bacterial enzyme that catalyzes formation of carbon monoxide. J Biol Chem 1993, 268:21466-9.
- 11. Wray JW, Abeles RH: The methionine salvage pathway in Klebsiella pneumoniae and rat liver. Identification and characterization of two novel dioxygenases. J Biol Chem 1995, **270:**3147-53.
- Ashida H, Saito Y, Kojima Ć, Kobayashi K, Ogasawara N, Yokota A: A functional link between RuBisCO-like protein of Bacillus and photosynthetic RuBisCO. Science 2003, 302:286-90.
- Murphy BA, Grundy FJ, Henkin TM: Prediction of gene function in methylthioadenosine recycling from regulatory signals. J Bacteriol 2002, 184:2314-8.
- 14. Sekowska A, Danchin A: The methionine salvage pathway in Bacillus subtilis. BMC Microbiol 2002, 2:8.
- Backlund PS Jr, Chang CP, Smith RA: Identification of 2-keto-4methylthiobutyrate as an intermediate compound in methionine synthesis from 5'-methylthioadenosine. J Biol Chem 1982, 257:4196-202.
- Berger BJ, English S, Chan G, Knodel MH: Methionine regeneration and aminotransferases in Bacillus subtilis, Bacillus cereus, and Bacillus anthracis. J Bacteriol 2003, 185:2418-31.
- Berger LC, Wilson J, Wood P, Berger BJ: Methionine regeneration and aspartate aminotransferase in parasitic protozoa. J Bacteriol 2001, 183:4421-34.
- Ghoda LY, Savarese TM, Dexter DL, Parks RE Jr, Trackman PC, Abeles RH: Characterization of a defect in the pathway for converting 5'-deoxy-5'- methylthioadenosine to methionine in a subline of a cultured heterogeneous human colon carcinoma. *J Biol Chem* 1984, 259:6715-9.
- Yocum RR, Perkins JB, Howitt CL, Pero J: Cloning and characterization of the metE gene encoding S- adenosylmethionine synthetase from Bacillus subtilis. J Bacteriol 1996, 178:4604-10.

- Sekowska A, Denervaud V, Ashida H, Michoud K, Haas D, Yokota A, Danchin A: Bacterial variations on the methionine salvage pathway. BMC Microbiol 2004, 4:9.
- 21. Berger BJ, Knodel MH: Characterisation of methionine adenosyltransferase from Mycobacterium smegmatis and M. tuberculosis. BMC Microbiol 2003, 3:12.
- Jansonius JN: Structure, evolution and action of vitamin B6dependent enzymes. Curr Opin Struct Biol 1998, 8:759-69.
- Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-44.
- Okada K, Hirotsu K, Hayashi H, Kagamiyama H: Structures of Escherichia coli branched-chain amino acid aminotransferase and its complexes with 4-methylvalerate and 2- methylleucine: induced fit and substrate recognition of the enzyme. Biochemistry 2001, 40:7453-63.
- 25. Cornish-Bowden A: A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. *Biochem J* 1974, 137:143-4.
- Bolkenius FN, Knodgen B, Seiler N: DL-canaline and 5-fluoromethylornithine. Comparison of two inactivators of ornithine aminotransferase. Biochem J 1990, 268:409-14.
- 27. Rosenthal GA: L-canaline: a potent antimetabolite and anticancer agent from leguminous plants. Life Sci 1997, 60:1635-41.
- Worthen DR, Ratliff DK, Rosenthal GA, Trifonov L, Crooks PA: Structure-activity studies of L-canaline-mediated inhibition of porcine alanine aminotransferase. *Chem Res Toxicol* 1996, 9:1293-7.
- Chan K, Knaak T, Satkamp L, Humbert O, Falkow S, Ramakrishnan L: Complex pattern of Mycobacterium marinum gene expression during long-term granulomatous infection. Proc Nat Acad Sci USA 2002, 99:3920-5.
- Berger BJ: Antimalarial activities of aminooxy compounds. Antimicrob Ag Chemother 2000, 44:2540-2.
- Yennawar NH, Conway ME, Yennawar HP, Farber GK, Hutson SM: Crystal structures of human mitochondrial branched chain aminotransferase reaction intermediates: ketimine and pyridoxamine phosphate forms. *Biochemistry* 2002, 41:11592-601.
- 32. Beeler T, Churchich JE: Reactivity of the phosphopyridoxal groups of cystathionase. J Biol Chem 1976, 251:5267-71.
- 33. Berger BJ, Dai WW, Wilson J: Methionine formation from alphaketomethiobutyrate in the trypanosomatid Crithidia fasciculata. FEMS Microbiol Letts 1998, 165:305-12.
- Wallace RJ, Nash DR, Steele LC, Steingrube V: Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986, 24:976-981.
- 35. Favour CB: Bacteriological study of cabroxymethoxylamine hemichloride. J Bacteriol 1948, 55:1-9.
- Price SA, Mamalis P, McHale D, Green J: The antimicrobial properties of some alpha-amino-oxy-acids, alpha-amino-oxyhydrazides, alkoxyamines, alkoxydiguanides and their derivatives. Bri J Pharmchemother 1960, 15:243-246.
- McHale D, Green J, Mamalis P: Amino-oxy-derivatives. Part I. Some α-amino-oxy-acids and α-amino-oxy-hydrazides. J Chem Soc 1960, 1960:225-229.
- Kisfaludy L, Dancsi L, Patthy A, Fekete G, Szabo I: alpha-Aminooxyacid derivatives with potent antituberculotic effect. Experientia 1971, 27:1055-1056.
- Mamalis P, Green J, McHale D: Amino-oxy-derivatives. Part II. Some derivatives of N-hydroxydiguanide. J Chem Soc 1960, 1960:229-238.
- McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr, Russell DG: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000, 406:735-8.
- Paulin L, Brander E, Poso H: Ornithine decarboxylase, S-adenosyl-L-methionine decarboxylase and arginine decarboxylase from Mycobacterium bovis (BCG). Experientia 1987, 43:174-6.

- 42. Sekowska A, Denervaud V, Ashida H, Michoud K, Haas D, Yokota A, Danchin A: **Bacterial variations on the methionine salvage** pathway. *BMC Microbiol* 2004, **4**:9.
- 43. Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Cummings NJ, Daniel RA, Denizot F, Devine KM, Dusterhoft A, Ehrlich SD, Emmerson PT, Entian KD, Errington J, Fabret C, Ferrari E, Foulger D, Fritz C, Fujita M, Fujita Y, Fuma S, Galizzi A, Galleron N, Ghim SY, Glaser P, Goffeau A, Golightly EJ, Grandi G, Guiseppi G, Guy BJ, Haga K, Haiech J, Harwood CR, Henaut A, Hilbert H, Holsappel S, Hosono S, Hullo MF, Itaya M, Jones L, Joris B, Karamata D, Kasahara Y, Klaerr-Blanchard M, Klein C, Kobayashi Y, Koetter P, Koningstein G, Krogh S, Kumano M, Kurita K, Lapidus A, Lardinois S, Lauber J, Lazarevic V, Lee SM, Levine A, Liu H, Llama FQ, Masuda S, Mauel C, Medigue C, Medina N, Mellado RP, Mizuno M, Moestl D, Nakai S, Noback M, Noone D, O'Reilly M, Ogawa K, Ogiwara A, Oudega B, Park SH, Parro V, Pohl TM, Portetelle D, Porwollik S, Prescott AM, Presecan E, Pujic P, Purnelle B, Rapoport G, Rey M, Reynolds S, Rieger M, Rivolta C, Rocha E, Roche B, Rose M, Sadaie Y, Sato T, Scanlan E, Schleich S, Schroeter R, Scoffone F, Sekiguchi J, Sekowska A, Seror SJ, Serror P, Shin BS, Soldo B, Sorokin A, Tacconi E, Takagi T, Takahashi H, Takemaru M, Tamakoshi A, Tanaka T, Terpstra P, Tognoni A, Tosato V, Uchiyama S, Vandenbol M, Vannier F, Vassarotti A, Viari A, Wambutt R, Wedler E, Wedler H, Weitzenegger T, Winters P, Wipat A, Yamamoto H, Yamane K, Yasumoto K, Yata K, Yoshida K, Yoshikawa HF, Zumstein E, Yoshikawa H, Danchin A: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature 1997, 390:249-56.
- Chou TC: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976, 59:253-76.
- 45. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL: GenBank. Nucl Acids Res 2003, 31:23-7.
- 46. Thompson JD, Higgins DG, Gibson TJ: **CLUSTAL W: improving** the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucl Acids Res* 1994, **22:**4673-80.
- Hall TA: Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999, 41:95-98.
- Felsenstein J: PHYLIP phylogeny inference package (version 3.2). Cladistics 1989, 5:164-166.
- Saitou N, Nei M: The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-25.
- Page RD: TreeView: an application to display phylogenetic trees on personal computers. Computer Appl Biosci 1996, 12:357-8.
- Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, Pryor M, Duthoy S, Grondin S, Lacroix C, Monsempe C, Simon S, Harris B, Atkin R, Doggett J, Mayes R, Keating L, Wheeler PR, Parkhill J, Barrell BG, Cole ST, Gordon SV, Hewinson RG: The complete genome sequence of Mycobacterium bovis. Proc Nat Acad Sci USA 2003, 100:7877-82.
- 52. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG: Massive gene decay in the leprosy bacillus. Nature 2001, 409:1007-11.
- 53. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA: Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 2002, 417:141-7.

- Bledsoe RK, Dawson PA, Hutson SM: Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim Biophys Acta 1997, 1339:9-13.
   Kuramitsu S, Ogawa T, Ogawa H, Kagamiyama H: Branched-chain
- 55. Kuramitsu S, Ogawa T, Ogawa H, Kagamiyama H: Branched-chain amino acid aminotransferase of Escherichia coli : nucleotide sequence of the ilvE gene and the deduced amino acid sequence. J Biochem 1985, 97:993-9.

